ArticleJournal of xenobiotics2026
Acute Anticholinergic Toxic Syndrome Due to Scopolamine Exposure: A Case Report with Possible Drug-Facilitated Administration.
Article in Journal of xenobiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionScopolamine is a tropane alkaloid and non-selective muscarinic receptor antagonist capable of inducing a central anticholinergic toxidrome with pronounced neuropsychiatric and autonomic manifestations. Despite its well-characterized pharmacology, diagnosis remains clinically challenging due to variable presentation and often absent or unreliable exposure history, particularly in non-medical contexts.
methodsWe report a case of a 34-year-old female presenting with an acute onset of altered mental status following a social event. Clinical findings included delirium, hallucinations, psychomotor agitation, dysarthria, bilateral mydriasis with preserved light reflex, sinus tachycardia, and marked urinary retention. Routine laboratory investigations were largely within normal limits, and standard urine toxicology screening was negative except for iatrogenic benzodiazepines. Given the characteristic toxidrome, extended toxicological analysis using gas chromatography-mass spectrometry (GC-MS) was performed, confirming the presence of scopolamine. Supportive treatment, including benzodiazepines and off-label intravenous galantamine, was administered, resulting in progressive clinical improvement and complete recovery without sequelae.
resultsThis case underscores the diagnostic limitations of routine toxicology screening for tropane alkaloids and highlights the importance of a pattern-based toxidrome approach. Given the absence of reliable exposure history and the presence of marked anterograde amnesia, an exogenous exposure cannot be excluded; however, no direct forensic evidence supports intentional administration. Furthermore, galantamine may represent a pharmacologically plausible alternative to physostigmine in settings where it is unavailable, although evidence remains limited.
conclusionsScopolamine intoxication should be considered in cases of acute anticholinergic syndrome with negative standard screening, and confirmation requires advanced analytical methods such as GC-MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.